Aeon Plans For Next Phase In Bid For Botox Biosimilar
Firm Says It Is ‘Aligned With FDA’ On Next Steps For A US Filing; Sets Out Study Plans
Aeon Biopharma has heralded its latest interaction with the US FDA over its planned Botox biosimilar as a win that sets the stage for analytical studies, trials and a subsequent filing.
